Antibody response to hepatitis B vaccine in substance use disorder patients

Hildi J. Hagedorn, Nancy A. Rettmann, Eric W. Dieperink, Janet Durfee, Bashar Aqel

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The objectives of this study were to assess the prevalence of prognostic factors previously known to be associated with poor antibody response to hepatitis B vaccination in a sample of veterans presenting for substance use disorders treatment at a Veterans Health Administration (VA) Medical Center, assess vaccination response, and identify markers for poor response in this population. Results indicated that most participants had multiple prognostic factors previously known to be associated with poor antibody response including male gender, age over 40, smoking, and obesity. The rate of seroconversion in this sample was 51.9%. This is substantially lower than seen in healthy adults. Alcohol dependence was the only significant independent negative predictor of seroconversion in this sample. Substance use disorders treatment providers who are considering adding hepatitis B vaccination services to their clinics should be aware that the antibody response to the hepatitis B vaccination is inconsistent and that patients with particular demographic characteristics may be at heightened risk of poor antibody response.

Original languageEnglish (US)
Pages (from-to)39-43
Number of pages5
JournalDrug and Alcohol Dependence
Volume107
Issue number1
DOIs
StatePublished - Feb 1 2010

Keywords

  • Hepatitis B vaccine
  • Hepatitis services
  • Substance abuse treatment programs
  • Substance use disorders
  • Veterans

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antibody response to hepatitis B vaccine in substance use disorder patients'. Together they form a unique fingerprint.

Cite this